This chapter reviews the new direct oral anticoagulants – thrombin and Xa inhibitors. The specific drugs are reviewed as well as the specific indications – prevention and treatment of deep venous thrombosis, stroke prevention in atrial fibrillation, and acute coronary syndrome. Finally, common issues such as monitoring and choosing the appropriate patient to use the drugs in are reviewed.
KeywordsApixaban Betrixaban Dabigatran Edoxaban Rivaroxaban
- López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, Okoli GN, Davies PA, Bodalia PN, Bryden PA, Welton NJ, Hollingworth W, Caldwell DM, Savović J, Dias S, Salisbury C, Eaton D, Stephens-Boal A, Sofat R. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017;359:j5058.CrossRefGoogle Scholar